After his medical residency at Massachusetts General Hospital in Boston and heme/onc fellowship at Memorial Sloan Kettering Cancer Center, he joined the Adult Bone Marrow Transplantation Service of MSKCC where he serves as an Assistant Attending. He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.
Research Interests
My research is focused on the mechanisms by which commensal bacteria modulate alloimmunity, both with respect to graft-vs-host disease (GVHD) and to graft-vs-tumor activity. My long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.
Awards
CIBMTR Best Abstract Award for Clinical Research ASBMT/ASTCT meetings 2016, 2018, and 2019
Community Service Award, Medical Society of the State of New York, June 2010
Alpha Omega Alpha, September 2009
Travel Award, American Society of Hematology, Annual Meeting, December 2005
Funding
- NHLBI K08 HL143189 01A1
- American Society for Blood and Marrow New Investigator Award (2019-2021)
- Society for MSKCC Research Grants (2018-2020)
- Parker Institute for Cancer Immunotherapy Career Development Award (2017-Present)
- Cancer Systems Immunology Pilot Award (2018)
- Parker Institute for Cancer for Cancer Immunotherapy Pilot Grant (2017-2018)
- Sawiris Foundation Myeloma and Transplant Research Award (2017-2018)
View a full listing of Jonathan U. Peled’s journal articles.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jonathan U. Peled discloses the following relationships and financial interests:
-
CSL Behring
Provision of Services (uncompensated) -
Da Volterra
Provision of Services -
French National Cancer Institute (INCa)
Provision of Services -
Hanson Wade Limited
Provision of Services -
HayMatick Meetings & Events
Provision of Services -
KongresKompagniet A/S
Provision of Services
-
MaaT Pharma
Provision of Services -
Seres Therapeutics
Intellectual Property Rights -
University Hospital Regensburg
Provision of Services (uncompensated) -
University of Nebraska Medical Center
Provision of Services -
William Blair & Company, L.L.C.
Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
View all disclosures
